These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3068316)

  • 1. Biochemical host response to interferon-beta.
    Liberati AM; Fizzotti M; Proietti MG; Di Marzio R; Schippa M; Biscottini B; Senatore M; Berruto P; Canali S; Peretti G
    J Interferon Res; 1988 Dec; 8(6):765-77. PubMed ID: 3068316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
    Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
    J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced serum levels of beta-2-microglobulin, neopterin, and interferon-gamma in patients treated with recombinant tumor necrosis factor-alpha.
    Aulitzky WE; Tilg H; Herold M; Berger M; Vogel W; Judmaier G; Gastl G; Mull B; Flener R; Wiegele J
    J Interferon Res; 1988 Oct; 8(5):655-64. PubMed ID: 3148671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta.
    Liberati AM; Horisberger MA; Palmisano L; Astolfi S; Nastari A; Mechati S; Villa A; Mancini S; Arzano S; Grignani F
    J Interferon Res; 1992 Oct; 12(5):329-36. PubMed ID: 1431312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
    Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
    Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
    J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation.
    Tilg H; Vogel W; Aulitzky WE; Herold M; Königsrainer A; Margreiter R; Huber C
    Transplantation; 1990 Jun; 49(6):1074-80. PubMed ID: 2163132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of biological effects of orally administered interferon-beta ser.
    Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC
    J Interferon Res; 1992 Dec; 12(6):411-3. PubMed ID: 1289408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
    Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
    J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
    Fuchs D; Norkrans G; Wejstal R; Reibnegger G; Weiss G; Weiland O; Schvarcz R; Fryden A; Wachter H
    Eur J Med; 1992; 1(4):196-200. PubMed ID: 1341444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.
    Chiang J; Gloff CA; Yoshizawa CN; Williams GJ
    Pharm Res; 1993 Apr; 10(4):567-72. PubMed ID: 8483840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
    Aulitzky W; Gastl G; Aulitzky WE; Herold M; Kemmler J; Mull B; Frick J; Huber C
    J Clin Oncol; 1989 Dec; 7(12):1875-84. PubMed ID: 2511277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.
    Aulitzky W; Gastl G; Aulitzky WE; Nachbaur K; Lanske B; Kemmler G; Flener R; Frick J; Huber C
    Immunobiology; 1987 Dec; 176(1-2):85-95. PubMed ID: 3129362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
    Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
    Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia.
    Liberati AM; Horisberger MA; Garofani P; De Angelis V; Ferrajoli A; Di Clemente F; Caricchi P; Adiuto D; Fedeli L; Palumbo B
    J Interferon Res; 1994 Dec; 14(6):349-55. PubMed ID: 7897254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.